Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 04, 2021

SELL
$62.14 - $81.82 $785,449 - $1.03 Million
-12,640 Closed
0 $0
Q1 2021

May 04, 2021

BUY
$59.42 - $85.46 $466,090 - $670,348
7,844 Added 163.55%
12,640 $974,000
Q4 2020

Feb 08, 2021

BUY
$40.64 - $61.38 $194,909 - $294,378
4,796 New
4,796 $288,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.54B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Migdal Insurance & Financial Holdings Ltd. Portfolio

Follow Migdal Insurance & Financial Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.